Venous Thromboembolism Treatment Market

Venous Thromboembolism Treatment Outlook - 2022-2029

[243 Pages Report] The global Venous Thromboembolism Treatment Market is expected to exceed US$ 1.53 Bn by 2022. Growing acceptance of novel venous thromboembolism treatment devices in emerging economies such as India, China, Brazil, and Russia among others is estimated to facilitate the growth in the market.

Future Market Insights (FMI) states that the demand in the global venous thromboembolism treatment market is projected to surge at 3.7% CAGR during the forecast period 2022-2029.

The deep venous thrombosis segment is anticipated to account for more than 3/5th of venous thromboembolism treatment sales by 2022, reveals FMI. Also, percutaneous thrombectomy devices and catheter-directed thrombolysis devices are estimated to collectively account for over half of the demand share through 2029.

2014-2021 Venous Thromboembolism Treatment Market Outlook in Comparison to 2022-2029 Growth Forecast

Sales in the global venous thromboembolism treatment market totaled US$ 1.46 Bn in 2021, as per FMI. The market is estimated to expand by 1.5x over the forecast period 2022-2029

Venous thromboembolism is a condition in which blood clots are formed in deep veins of arms, groin, or legs and travels with the blood circulation, lodging in the lungs. It can restrict the flow of blood and oxygen damaging the body’s tissues and organs. Hence, growing awareness regarding the severity of the diseases across developing economies is favoring the growth in the market.

Rising prevalence of pulmonary embolism disease is one of the leading factors favoring the growth in the market. For instance, according to the Centers for Disease Control and Prevention, around 900,000 people in the U.S. are affected by pulmonary embolism, causing around 60,000 to 100,000 deaths every year.

As several patients are at high risk of developing more serious venous thromboembolism, therapeutics such as retrievable vena cava filters are increasingly being used to stop the progression of malignant pulmonary embolism. This is expected to augment the sales of venous thromboembolism treatments in the market.

Request comprehensive report brochure

Will the Rising Surgical Procedures Drive Venous Thromboembolism Treatment Market?

A substantial rise in surgical procedures conducted worldwide is registered over the last few years. This can be attributable to the rising burden of various chronic ailments around the world. Moreover, higher demand for cosmetics surgeries also will create opportunities for growth of the market.

According to a report by the American Society of Plastic Surgeons, around 15.6 million cosmetic procedures and 6.8 million reconstructive procedures were reported to be conducted across the U.S. in 2020. As surgical procedures increase the risk of blood clots in the body causing pulmonary embolism, this rise in surgeries is expected to create high demand for the prevention and therapeutics of the disease, creating growth opportunities in the market.

In addition, increasing number of research and development (R&D) activities for the development of novel devices, filters, and therapeutics across countries such as the U.S., China, the U.K., and India are favoring the growth in the market. On account of this, the global venous thromboembolism treatment market is poised to total US$ 1.91 Bn through 2029, expanding at 3.7% CAGR during the forecast period.

Country-wise Analysis

What are the Factors Facilitating the Growth in the U.S. Venous Thromboembolism Treatment Market?

“Favorable Reimbursement Policies Favoring Demand for Thromboembolic Therapy in the U.S.”

As per Future Market Insights (FMI), the U.S. is estimated to emerge as one of the largest revenue-generating markets for venous thromboembolism treatment.

Presence of favorable reimbursement policies facilitating treatment of various diseases, covering procedures such as chemotherapy and thromboembolic therapy in the U.S. is favoring the growth in the market. In addition, the country also offers high incentives to doctors and physicians to use filters for prophylactic treatments. These factors are estimated to accelerate the sales of venous thromboembolism treatments in the U.S.

Why is the Sales of Venous Thromboembolism Treatment Increasing in the U.K.?

“Growing Retrieval Rate of Vena Cava Filters to Push Demand for Venous Thromboembolism Management”

FMI states that the U.K. is anticipated to account for a significant share in the Europe venous thromboembolism treatment market over the assessment period.

Vena cava filters can cause serious medical complications post-surgical implantation. Hence, these filters have to be removed once the risk of pulmonary embolism declines.

With rising instance of vena cava filters being left inside patients, the demand for venous thromboembolism management rapidly increasing. Thus, market players in the country are aiming at developing advanced tracking systems for patients follow-up to ensure the removal of these filters. Such developments in the country are facilitating the growth in the market.

Why is the Demand for Venous Thromboembolism Treatment Burgeoning in China?

“Increasing Burden of Lifestyle Diseases Fueling the Venous Thromboembolism Treatment Device Sales”

The China venous thromboembolism treatment market is projected to register growth at a rapid CAGR between 2022 and 2029, as per FMI.

Growing prevalence of lifestyle disorders such as diabetes, obesity, low blood pressure, and others are significantly increasing the burden of pulmonary embolism as these disorders increase the risk of blood clots.

As venous thromboembolism treatment devices such as thrombectomy devices and blood clot retrieval devices assist in dissolving the blood clots at initials stages. Consequently the rising demand for these devices is favoring the growth in the country.

Category-wise Insights

Which Product Category Holds Dominance?

“Rising Inclination towards Minimally Invasive Treatment Augmenting the Demand Venous Thromboembolism Management Devices”

Future Market Insights forecasts catheter-directed thrombolysis devices to account for maximum venous thromboembolism treatment sales through 2029.

Catheter-directed thrombolysis devices are popular adjunct to percutaneous mechanical thrombectomy devices which uses x-ray imaging to guide medical device or medication to the site of blood clots and dissolve it.

Hence, growing patient inclination towards adopting minimally invasive procedures for the treatment of pulmonary embolism is propelling the demand for such venous thromboembolism management devices, driving the growth in the segment.

Why is the Deep Venous Thrombosis Leading the Market?

“Growing Risk of Blood Clots to Create Tailwind for Deep Venous Thrombosis Treatment”

As per FMI, the deep venous thrombosis segment is estimated to lead the global venous thromboembolism treatment market in terms of disease indication. It is expected to account for nearly 68.4% of the total sales in 2022.

Increasing risk of blood clots, causing deep venous thrombosis, due to growing cases of cancer, pregnancy, and cardiovascular diseases, especially across developing economies such as China, India, Australia, and others is propelling the demand in the deep venous thrombosis segment.

Why is the Sales of Venous Thromboembolism Treatment Rising in Hospitals?

“Presence of Favorable Reimbursement Policies to Augment the Sales of Thromboembolism Treatment”

In terms of end user, the global venous thromboembolism treatment market is segmented into hospital, catheterization laboratories, and ambulatory surgical centers. FMI states that the hospital segment is projected to register robust growth in the market during the forecast period.

Increasing patient preference for visiting hospitals for the treatment of pulmonary embolism and deep venous thrombosis, owing to the presence of advanced medical infrastructure and favorable reimbursement policies is favoring the growth in the segment. 

Competitive Landscape

Key players in the global venous thromboembolism treatment market are investing in research and development activities for launching novel devices and therapeutics. Some of the other companies are aiming at receiving product approvals for their new products to gain competitive edge. For instance,

In June 2021, Janssen Pharmaceuticals, Inc, a Belgium-based pharmaceutical company, announced receiving Food and Drug Administration (FDA) approval for its new products XARELTO® (rivaroxaban) for the treatment of two indications - deep venous thrombosis and pulmonary embolism. This will assist the company to strengthen its footprint in the market.

Scope of the Report

Venous Thromboembolism Treatment Market by Category

By Product:

• Non-Segmented Pneumatic Compression Pumps
• Segmented Pneumatic Compression Pumps without Gradient
• Segmented Pneumatic Compression Pumps with Calibrated Gradient
• Upper Pneumatic Compression Sleeves
• Lower Pneumatic Compression Sleeves
• Permanent Inferior Vena Cava Filters
• Retrievable Inferior Vena Cava Filters
• Embolectomy Balloon Catheters
• Percutaneous Thrombectomy Devices
• Catheter-Directed Thrombolysis (CDT) Devices

By Disease Indication:    

• Deep Venous Thrombosis
• Pulmonary Embolism

By End User:

• Hospitals
• Catheterisation Laboratories
• Ambulatory Surgical Centers

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa